Invalidity dossier
US 10265402
Absorption enhancers for drug administration
Current assignee: Aegis Therapeutics LLC
Added 9/23/2026, 12:14:32 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US10265402B2
Title: Absorption enhancers for drug administration
Patent number: US10265402B2 (application US15/942,110; pre-grant publication US20180221489A1)
Inventor: Edward T. Maggio
Assignee: Aegis Therapeutics LLC (original and current assignee listed)
Key dates from the supplied record:
- Priority date: 2004-08-25
- Filing date: 2018-03-30
- Publication date: 2019-04-23
- Anticipated expiration: 2025-05-11
- Legal status: Expired – Lifetime
Purpose and plain-language scope:
The patent concerns therapeutic compositions combining at least one biologically active compound (for example, a GLP-1 peptide or incretin mimetic, or insulin) with at least one surfactant, where the surfactant consists of an alkyl glycoside and/or a saccharide alkyl ester or sucrose ester. The stated goal is to stabilize the biologically active compound for at least about 6 months, or more, from about 4°C to about 25°C, and to increase absorption of drugs that are otherwise poorly absorbed.
The disclosed absorption enhancer is described as a nontoxic, nonionic alkyl glycoside having a hydrophobic alkyl group joined by a linkage to a hydrophilic saccharide. Methods are described for treating diabetes by administering a blood-glucose-reducing amount of the composition via oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, or oral cavity (sublingual or buccal) routes, and for treating congestive heart failure using a GLP-1 peptide or functional equivalent.
Classification excerpts cover medicinal preparations characterized by non-active ingredients (sugar alcohols, saccharides, polysorbates) and site-specific forms (buccal, sublingual, nasal, ocular, peroral).
What the excerpt does not establish:
The supplied text does not include the full claims, a complete specification, examples, or data. It does not establish claim scope, validity, enforceability, inventorship disputes, or the accuracy of the listed assignee, dates, or legal status. The record further does not establish any litigation, ownership transfer, or prior art, which were outside the scope of this overview. Statements above reflect only the excerpted Google Patents source.
Source: https://patents.google.com/patent/[US10265402](/patent/US10265402)/en
Generated 10/1/2026, 9:53:45 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 10265402. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.